Hospital Antibiotic Policy Date of Issue :

30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

ANTIBIOTIC POLICY
POLICY & PROCEDURE

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 1 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

INTRODUCTION
Antibiotics are essential treatments for serious infections. They are one of the most
important and valuable discoveries of modern medicine. However administration of antibiotics
can lead to the selection of antibiotic-resistant organisms. These organisms can give rise to
healthcare-associated infections which are associated with increased morbidity and mortality.
Therefore it is important to ensure that antibiotics are prescribed in a way which
minimizes the risk of healthcare-associated infections. Hospital Antibiotic Guidelines have been
designed to treat common infections effectively and with the minimum risk of healthcare-
associated infections. The current antibiotic policy describes the procedures to encourage the use
of the Antibiotic Guidelines and to ensure that antibiotics are not prescribed in a way which is
likely to lead to healthcare-associated infections.
This policy deals with the processes by which recommendations for specific antibiotic
treatments are made and the procedures to support these recommendations. It does not provide
specific advice on which antibiotics should be used in specific infections as this is covered in the
Drug Formulary Antibiotic Guidelines. This policy also does not provide information on which
antibiotics are regarded as having the highest risk of causing healthcare-associated infections nor
on which antibiotics can only be used following advice from a microbiologist or infectious
diseases physician. This is because this will vary between clinical areas depending on recent
infection surveillance data.

PURPOSE OF THIS POLICY

The aim of implementing this policy throughout the hospital is to ensure that antibiotics are used
appropriately. This should result in more effective treatment of infections so that patient
outcomes are optimized. In addition appropriate antibiotic use should minimize the risk of
healthcare-associated infections occurring and this produces benefits for patients and staff and
for service delivery and clinical outcomes.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 2 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

1. Anti-Microbial Pre-Operative Prophylaxis Guidelines

Ideally, an antimicrobial agent for surgical prophylaxis should (1) prevent SSI, (2) prevent SSI-
related morbidity and mortality, (3) reduce the duration and cost of health care (when the costs
associated with the management of SSI are considered, the cost-effectiveness of prophylaxis
becomes evident), (4) produce no adverse effects, and (5) have no adverse consequences for the
microbial flora of the patient or the hospital.53
To achieve these goals, an antimicrobial agent should be (1) active against the pathogens most
likely to contaminate the surgical site, (2) given in an appropriate dosage and at a time that
ensures adequate serum and tissue concentrations during the period of potential contamination,
(3) safe, and (4) administered for the shortest effective period to minimize adverse effects, the
development of resistance, and costs
These Recommendations are provided for adult (age 19 years or older) and pediatric (age 1–
18years) patients. These guidelines do not specifically address newborn(premature and full-term)
infants.
While the guidelines do not address all concerns for patients with renal or hepatic dysfunction,
antimicrobial prophylaxis often does not need to be modified for these patients when given as a
single preoperative dose before surgical incision.
The recommendations herein may not be appropriate for use in all clinical situations. Decisions
to follow these recommendations must be based on the judgment of the clinician and
consideration of individual patient circumstances and available resources.

a. Preoperative-dose timing:
Successful prophylaxis requires the delivery of the antimicrobial to the operative site before
contamination occurs. Thus, the antimicrobial agent should be administered at such a time to
provide serum and tissue concentrations exceeding the minimum inhibitory concentration (MIC)
for the probable organisms associated with the procedure, at the time of incision, and for the
duration of the procedure.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 3 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Overall, administration of the first dose of antimicrobial beginning within 60 minutes before
surgical incision is recommended.
Administration of vancomycin and fluoroquinolones should begin within 120 minutes before
surgical incision because of the prolonged infusion times required for these drugs. Because these
drugs have long half-lives, this early administration should not compromise serum levels of these
agents during most surgical procedures.

b. Selection and dosing:

To ensure that adequate serum and tissue concentrations of antimicrobial agents for prophylaxis
of SSIs are achieved, antimicrobial specific pharmacokinetic and pharmacodynamics properties
and patient factors must be considered when selecting a dose.
It seems advisable to administer prophylactic agents in a manner that will ensure adequate levels
of drug in serum and tissue for the interval during which the surgical site is open.

Weight-based dosing: The dosing of most antimicrobials in pediatric patients is based on body
weight, but the dosing of many antimicrobials in adults is not based on body weight, because it is
safe, effective, and convenient to use standardized doses for most of the adult patient population.
However, in obese patients, especially those who are morbidly obese, serum and tissue
concentrations of some drugs may differ from those in normal-weight patients because of
pharmacokinetic alterations that depend on the lipophilicity of the drug and other factors.
Obesity has been recognized as a risk factor for SSI; therefore, optimal dosing of antimicrobial
prophylaxis is needed in these patients.

c. Redosing.
Intraoperative redosing is needed to ensure adequate serum and tissue concentrations of the
antimicrobial if the duration of the procedure exceeds two half-lives of the antimicrobial or there
is excessive blood loss (i.e., >1500 mL)

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 4 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

The redosing interval should be measured from the time of administration of the preoperative
dose, not from the beginning of the procedure.
Redosing may also be warranted if there are factors that shorten the half-life of the antimicrobial
agent (e.g., extensive burns)
Redosing may not be warranted in patients in whom the half-life of the antimicrobial agent is
prolonged (e.g., patients with renal insufficiency or renal failure)

d. Duration.:
The duration of antimicrobial prophylaxis should be less than 24 hours for most procedures.
A cardiothoracic procedure for which prophylaxis duration of up to 48 hours has been accepted
without evidence to support the practice is an area that remains controversial.
Moreover, prolonged prophylaxis was associated with an increased risk of acquired antimicrobial
resistance compared with short-term prophylaxis
There are no data to support the continuation of antimicrobial prophylaxis until all indwelling
drains and intravascular catheters are removed

e. Drug administration
The preferred route of administration varies with the type of procedure, but for a majority of
procedures, i.v. administration is ideal because it produces rapid, reliable, and predictable serum
and tissue concentrations.

f. Patients with prosthetic implants.

For patients with existing prosthetic implants who undergo an invasive procedure, there is no
evidence that antimicrobial prophylaxis prevents infections of the implant. However, updated
guidelines from the American Heart Association (AHA) suggest that prophylaxis may be
justified in a limited subset of patients for the prevention of endocarditis.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 5 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

g. Drug of choice:
For most procedures, cefazolin is the drug of choice for prophylaxis because it is the most widely
studied antimicrobial agent, with proven efficacy. It has a desirable duration of action, spectrum
of activity against organisms commonly encountered in surgery, reasonable safety, and low cost.
Routine use of vancomycin prophylaxis is not recommended for any procedure.8 Vancomycin
may be included in the regimen of choice when a cluster of
MRSA cases (e.g., mediastinitis after cardiac procedures) or methicillinresistant coagulase-
negative staphylococci SSIs have been detected at an institution. Vancomycin prophylaxis
should be considered for patients with known MRSA colonization or at high risk for MRSA
colonization in the absence of surveillance data (e.g., patients with recent hospitalization,
nursing-home residents, hemodialysis patients).
In institutions with SSIs attributable to communityassociated MRSA, antimicrobial agents with
known in vitro activity against this pathogen may be considered as an alternative to vancomycin.
The use of vancomycin for MRSA prophylaxis does not supplant the need for routine surgical
prophylaxis appropriate for the type of procedure.
When vancomycin is used, it can almost always be used as a single dose due to its long half-life.
Patients receiving therapeutic antimicrobials for a remote infection before surgery should also be
given antimicrobial prophylaxis before surgery to ensure adequate serum and tissue levels of
antimicrobials with activity against likely pathogens for the duration of the operation.
If the agents used therapeutically are appropriate for surgical prophylaxis, administering an extra
dose within 60 minutes before surgical incision is sufficient. Otherwise, the antimicrobial
prophylaxis recommended for the planned procedure should be used.
For patients with indwelling tubes or drains, consideration may be given to using prophylactic
agents active against pathogens found in these devices before the procedure, even though
therapeutic treatment for pathogens in drains is not indicated at other times.
For patients with chronic renal failure receiving vancomycin, a preoperative dose of cefazolin
should be considered instead of an extra dose of vancomycin, particularly if the probable

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 6 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

pathogens associated with the procedure are gram-negative. In most circumstances, elective
surgery should be postponed when the patient has an infection at a remote site.
h. Allergy to b-lactam antimicrobials.
Allergy to b-lactam antimicrobials may be a consideration in the selection of surgical
prophylaxis. The b-lactam antimicrobials, including cephalosporins, are the mainstay of surgical
antimicrobial prophylaxis and are also the most commonly implicated drugs when allergic
reactions occur. Because the predominant organisms in SSIs after clean procedures are gram-
positive, the inclusion of vancomycin may be appropriate for a patient with a life-threatening
allergy to b-lactam antimicrobials.
Although true Type 1 (immunoglobulin E [IgE]-mediated) crossallergic reactions between
penicillins, cephalosporins, and carbapenems are uncommon, cephalosporins and carbapenems
should not be used for surgical prophylaxis in patients with documented or presumed
IgEmediated penicillin allergy.
Refer
Annexure 1: Recommended doses and redosing intervals for commonly used antimicrobials
Annexure 2: Recommendations for surgical antimicrobial prophylaxis

Antibiotic timing
Duration of prophylaxis
Infusion of the first antimicrobial dose should begin within 60 min
before the surgical incision except for vancomycin and quinolones.
When fluroquinolones or vancomycins are indicated, infusions of
the 1st antimicrobial dose should begin within 120 min before the
incision.
Prophylactic antimicrobials should be discontinued within 24 h
after the end of surgery. Patients who have documented infection
at the time of surgery or within 24 hrs of surgery are excluded
from 24 hrs rule. Additionally post CT surgery patient allowed
upto 48 hrs of treatment.

Screening for b-lactam For those operations for which cephalosporins represent the most
allergy appropriate antimicrobials for prophylaxis, the medical history
should be adequate to determine whether the patient has a history
of allergy or serious adverse antibiotic reaction. Alternative testing
strategies (e.g., skin testing) may be useful for patients with
reported allergy.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 7 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

2. EMPERICAL TREATMENT FOR INFECTION

2.1.INFECTIVE ENDOCARDITIS ( Follow theEmpirical Treatment)

Native valves Ampicillin(12g/d)+Fluoxacillin(12g/d) OR
Ceftriaxone 2gm IV Q24H + Gentamycin
3mg/Kg IV 1dose.
In Pt’s allergic to Penicillin Vancomycin 15mg/kg IV Q12H+ Gentamycin.
Prosthetic valves Vancomycin 15mg/kg IV Q12H + Gentamycin
3mg/kg IV 1 dose +Rifampicin 900mg in 2-3
divideddoses.

2.2.URINARY TRACT INFECTIONS

Uncomplicated Cystitis . Nitrofurantoin Monohydrate 100mg PO Q12H
for 5 days or
.
Trimethoprim – Sulphamethoxazole (160/800)
PO Q12H for 3 days .
Fosfomycin 3gm once daily.
Note:If recommended agents cannot be used
Alternatives
because of known resistance or patient
Amoxicillin/clavulanate,Cefpodoxime.
intolerance
Complicated Cystitis
(For Men and Women) Cefaperazonesulbactum 1.5 gmsBD .
Complicated Cystitis Nitrofurantoin Monohydrate 100mg Q12H for
7 days or
(For Pregnant Women)
Trimethoprim – Sulphamethoxazole (160/800)
PO Q12H for 3 days
Uncomplicated Pyelonephritis Cefaperazone-Sulbactum 1.5 to 3gm IV Q12H
/ Ertapenem 1gm IV/IM once daily or

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 8 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Aztreonam 1.5 to 2gm IV Q8H (if Pt’s allergic

to penicillin)

Complicated Pyelonephritis Imipenem-cilastin 500mg Q6H, OR

Asymptomatic Bacteriuria*
Meropenem 1gm IV Q8Hly or Imipenem-
cilastin 500mg Q6H (if pt. in septic
shock)Consider adding Vancomycin
/linizolid& Teicoplanin.
No Role for Antibiotic usage

* To be treated with antibiotics in Pregnant women or undergoing Urological intervention

and Renal transplant patients..
2.3.CATHETER RELATED BLOOD STREAM INFECTIONS:( Follow the Empirical
Treatment)

Cefaperazone + Sulbactum + Vancomycin (30mg/kg/d)/Teicoplanin

Or
Piperacillin + Tazobactum
OR
Imipenem+cilastatin OR Meropenem,if patient in shock on BL- BLI.

2.4.CNS INFECTIONS
2.4.a. Brain abscess .
Simple Complex (Following surgical procedure, Head
trauma, Inf. Endocarditis)
1. Ceftriaxone 2gms / BD 1. Ceftriaxone 2gms / BD or Ceftazidime
+ / TDS 2gms
Metronidazole 500mg / TDS +
Metronidazole 500mg / TDS +
Vancomycin 30mg / kg / day
1. Ceftazidime 2gms / IV TDS (in
immunosuppressed)

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 9 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

+
Metronidazole 500mg / TDS

2.4.b. Meningitis:
Neonates Cefotaxime (12g / day) + ampicillin (150mg / kg / day)
4 – 12 weeks Ceftriaxone (100mg / kg / day) + ampicillin (150mg / kg / day)
3m – 18 years Ceftriaxone (100mg /kg/day) + Vancomycin 30mg / kg / day
18 – 50 years Ceftriaxone 2gm IV Q12H + Vancomycin 30mg/kg/day
Above 50 years Ceftriaxone 2gm IV Q12H + Vancomycin 30mg/kg/day+Augumentin
Immunocompromised Ceftazidime 2gms / IV Q8H+ Amikacin (15mg / kg / day) +
Vancomycin 30mg / kg / day
Basilar skull fracture Ceftriaxone (2gm IV Q12H + Vancomycin 30mg / kg / day+If any CSF
leak
Head injury Ceftazidime 2gm IV Q8H + Vancomycin 30mg / kg / day ,with CSF
leak (Rhinorrhea,otorrhea.)
CSF Shunt Ceftrioxone 2gm IV Q8H + Vancomycin 30mg / kg / dayOR if counts
,protein.
Penicillin allergy Vancomycin 30mg / kg / day + Carbapenem (Meropenem 1gm IV Q8H)

2.5.PNEUMONIA
Community acquired pneumonia
2.5.a. OUT PATIENT

No antibiotics used in the last 3 Azithromycin 500mg PO Q24H or

Months Clarithromycin 500mg PO Q12H or
Doxycycline 100mg PO Q12H
* Comorbidities present and no use of Macrolides(Azithromycin, Clarithromycin) +
antibiotics in last 3 months
Amoxicillin-clavulunate 625mg PO Q8H
Comorbidities present and recent use of Azithromycin 500mg PO Q24H and
antibiotics in last 3 months
Prepared by: Infection Control Committee Reviewed by: Consultants
Chairperson

Approved by: Medical Director Signature:

Page 10 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Pipericillin-tazobactum .
Risk factors/Epidemic of H1N1 Add Oseltamivir 75mg BD..

2.5.b. IN PATIENT -CAP

Non ICU Admission/in ward Pipericillintazobactum + Azithromycin 500mg

Risk factors for MDR pathogen
ICU admission * With risk factors of
pseudomonas
No Risk factors for MDR /Pseudomonas.
OD IV OR oral.
Meropenem/Imipenem +Azithromycin+
Linezolid .
Pipericillin-tazobactum4.5gm Q6H or
Meropenem(If pt has severe CAP /shock OR
Imipenem-Cilastin& Levofloxacin.
Amoxyclav + Azithromycin 500 mg OD

ICU admission with * Risk factors for CA – Piperacillin-Tazobactum 4.5 gm IV Q6H +

MRSA Azithromycin 500mg IV Q24H + Linezolid
600mg IV Q12H/ Teicoplanin.
If Patient’s allergic to Penicillin’s Aztreonam+Azithromycin
VAP /HAP Meropenem 1gm Q8H or Imipenem-cilastin +
Levofloxacin +Linezolid600mg IV
Q12H./Teicoplanin

Risk factors for pseudomonas:

1. Structural lung disease. (bronchiectasis), Cystic Fibrosis

2. Repeated exacerbation of COPD with recent steroids (10 mg/ d) + antibiotics usage.

3. Prior antibiotic therapy.( > 7 days in last 1 month)

4. Sputum / Blood – Consistent on gram stain.

5. Malnutrition

6. Immunocompromised state

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 11 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

7. Parenteral feeding

Risk factors for CA – MRSA

1. End stage Renal Disease/ Pt. on Hemodialysis
2. Drug (IV) abuse
3. Recurrent influenza
4. Prior antibiotic treatment – fluoroquinolones.
8. 5. Presence of cavitating lung lesion without risk for aspiration.
Duration of treatment for CAP : CAP due to Pseudomonas aeruginosa -14 days.
Necrotising pneumonia due to MDR Gram negative bacilli
- 14-21days.
Non-MDR – 7 -10 days.
Risk factors for MDR organism :
1. Age >65 yrs
2. Antibiotic usage in last 3 months.
3. Hospitalisation for >48hrs in preceding3 months.
4. Receiving immunosuppression treatment.
5. On chronic dialysis.
6. High incidence/persistence of MDR in community
7. Use of Steriods.
8. Receiving home infusions including antibiotics.

8.1.Surgical site infections

2.6.a. Clean wound of trunk, head, neck or extremities
Cefazolin 1gm 8th hourly or Clindamycin 600mg 8th hourly till culture is available.
2.6.b. Wound of perineum, operation of GI, genitourinary tract
Cefaperazone-sulbactum +Metronidazole
If MRSA risk-Vancomycin / Linezolid in discretion of clinician.

If patient sepsis send culture & prescribe IV linezolid &PiperecillinTazobactum

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 12 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Stable – Augmentin (Amoxicillin-clavulanate)

8.2.Skin & Soft tissue infections (SSTI)

Cellulitis Stable Patient OP Amoxyclav 625mg TID.
Cellulitis – admitted co-morbid Pipercillin-tazobactum + Clinidamycin.
conditions
Necrotizing /Sepsis/Aseptic shock : Clindamycin +Meropenem

8.3.Gastro intestinal & Abdominal & Infections

Acute Gastroenteritis No Antibiotics needed

Amoebic Dysentery Metronidazole 400mg PO Q8H

Enteric Fever(admitted OP) Ceftriaxone 200mg BD.Cefexime

Acute Cholecystitis Piperacillin-Tazobactum 4.5 gm IV Q6H

Acute Cholecystitis with shock/advanced Imipenem-cilastin./Meropenem.

age
Spontaneous Bacterial Peritonitis. Piperacillin-Tazobactum 4.5 gm IV Q6H.

Secondary Peritonitis(community acquired) loading dose followed by 50mg IV Q12H or

Piperacillin-Tazobactum 4.5 gm IV
Q6H/Carbapenems (if in shock)
Secondary Peritonitis(If patient in Imipenem-cilastin +Meropenem + Metronidazole
shock/sick
Ameobic Liver Abscess. Metronidazole 750mg IV Q8H for 10 days

If evidence of intradermal infection with Add Metronidazole.

distal small bowel,appendix,colon, proximal
GI perforation

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 13 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Health care associated intra abdominal Piperacillin-Tazobactum .If risk –

infections. Carbepenem+Teicoplanin + Metronidazole

9. ANTIBIOTIC POLICY FOR PEDIATRIC AND PEDIATRIC CARDIOLOGY

DEPARTMENT

9.1.EMPIRICAL ANTIBIOTICS
1. CARDIAC CATHETERISATION

2. All Pediatric Surgery – Inj.Cefaperazone +sulbactum 60 mg/kg/dose/8th hourly,

Inj.Amikacin 7.5 mg/kg/dose 12th hrly.

 Only for cath- Cefuroxime - 25 mg /kg/ dose 8thhrly

3. PRE-OPERATIVE PNEUMONIAS

A. Community acquired
 1st line - Amoxicillin &clavulanic acid (100 mg/kg/day in 3 divided doses)
 2nd line – (Magnex,CefeperazoneSulbactum)_+Amikacin to be added if required
 2nd line- Meropenum,cilaneum+ Amikacin+/- Linezolid
 3rd line- Meropenum,cilaneum+ Linezolid +/- Amikacin
Dose of Imipenem-cilastin -100mg/kg/day divided in 4 doses 6th hrly.
Dose of Colistin- Loading dose – 50000 units/kgover 1hr followed by 30000units/kg 8th
hrly.
9.2.Nosocomial
 Cefaperazone-sulbactum_+ Amikacin (15 mg/kg/ day in 3 divided doses

 2nd line- Meropenum/Cilanem+Linezolid +/- Amikacin

If gram positive infection is suspected Teicoplanin to be added

Later up gradation depends on throat secretions and blood culture reports as per sensitivity
pattern.
Prepared by: Infection Control Committee Reviewed by: Consultants
Chairperson

Approved by: Medical Director Signature:

Page 14 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

9.3.POST OPERATIVE

 Cefaperazone+ sulbactum(60mg/kg/day) in 3divided doses 8th hrly & Amkacin (15

mg/kg/day) in divided in 2 doses 12th hrly.
Duration 48 hrs only
If signs of infection are present, septic screening is done and antibiotics up graded as per culture,
sensitivity reports.
Methicillin resistant steptococcal pneumonia (MRSA)
 Vancomycin (10 mg/kg/dose 6th hourly

Vancomycin if culture sensitivity reports suggest

Second line antibiotics- Cilanem+ Amikacin+/-Teicoplanin until culture report available.

3.4. LRTI (LOWER RESP: TRACT INFECTION)

3.4.a. COMMUNITY ACQUIRED PNEUMONIA (CAP) – OPD

AGE I LINE ALTERNATIVES

3 Months – 5 Months Amoxicillin Coamoxiclav
30 – 50 mg/kg/day (40mg/kg/day)
> 5 years Amoxicillin Coamoxiclav
30 – 50 mg/kg/day (10 – 20 mg/kg/day)

3.4.b. COMMUNITY ACQUIRED PNEUMONIA (CAP) – IPD

AGE I LINE ALTERNATIVES

3 Months Amoxicillin ceftriaxone(100mg/kg/day)
30 – 50 mg/kg/day.
Aminoglycosides
>5 year Coamoxyclav Ceftriaxone +Amikacin(15mg/kg/day)

>5 year Coamoxiclav Ceftriaxone

& clarithromycin
(15mg/kg/day)
Azithromycin
(10mg/kg/day)

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 15 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Suspected staphylococcal pneumonia- ceftriaxone and Linizolid

Afebrile 1st line- Azithromycin

Febrile- 2nd line Cefperazonesulbactum + Clarithromycin

NOTE: Duration----7 to 14 days (Switch to oral therapy after 48 to 72 hrs)

3.5. (HAP) HEALTH CARE ASSOCIATED PNEUMONIA

EARLY ONSET HAP WITH NO PRIOR ANTIBIOTIC USE:

 Cefaperazone + sulbactum and Amikacin.

EARLY ONSET HAP WITH PRIOR ANTIBIOTIC USE / LATE ONSET HAP
 Amikacin + Cefaperazone
If ESBL rates are high / If child is sick - Start Imipenem+ cilastin & Amikacin.
 If MRSA ---- linezolid

3.6. SEPTICEMIA

AGENT Dose (mg/kg/day)

Neonates Ceftrioxone + Amikacin 100
<7 days Amikacin + 15
>7 day Ceftrioxone &Amikacin 100 + 5
If CNS infection is suspected Vancomycin 40

INFANTS AND CHILDREN

 Ceftriaxone 100mg/kg/day in 2 divided doses.

 If CNS infection or resistant streptococcus
pneumonia suspected Vancomycin added 60mg/kg/day in 4 divided doses
 Metronidazole
If intra-abdominal infection suspected – Clindamycin 30mg/kg/day in 2divided doses.

IMMUNO COMPROMISED

 Imipenem-cilastin 100 mg/kg/day in 4 divided doses.

 Vancomycin to be added if skin or mucus membrane infection present
Amikacin -15mg/kg/day in 2 divided doses.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 16 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

INFECTIVE ENDOCARDITIS

Prophylaxis Before Surgery

 Ampicilin – 50 mg/kg 1 hr before surgery
 Amikacin– 2.5 mg/kg 1 hr before surgery

Long Term Prophylaxis (for valvularlesson )

 Benzathinepencillin
>28 kg – 1.2 million international units (i.m)
<28 kg – 0.6 million international units (i.m)
10. EMPERICAL ANTIBIOTICS IN INFECTION

Penicillin - G - 2,00,000 kg/day in 4 divided doses

+
Amikacin—15 mg/kg/day in 2 divided doses 12th hrly.

Antibiotics are up graded as per culture sensitivity pattern

If cultures are negative, empirical antibiotics are upgraded depending on the type of valve lesion
and the suspected organism .

URINARY TRACT INFECTION

A. FOR CHEMOPROPHYLAXIS
 Cephalexin,Cefuroxime – 10 mg/kg/day in 3-4 divided doses for 6 months

B. TREATMENT (PARENTERAL)
 Cefotaxim – 100 – 150 mg/kg/day in 2-3 divided doses

 Amikacin – 15 mg/kg/day in twice a day.

C. TREATMENT (ORAL)
 Cephalexin – 10 mg/kg/day in 2 divided doses

Up gradation depending upon the cultures sensitivity patterns

If culture negative, quinolones are added if infection strongly suspected

11.Infusion of Higher Antibiotic: Paediatric dilution & rate

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 17 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

S. Antibiotics Infusion Rate Test Dose

No
1 Inj. Vancomycin 10-20ml Dilute in 20 No test dose
ml NS over1- 2hrs
2 Inj. Amphotercin 10-20ml Dilute in 5ml As per doctor
of 5% dextrose over instruction
1hrs.
3 Inj. Colistin Dilute in 10-20ml over No test dose
1hr..
4 All cephalosporins(Cefotaxime, Dilute in 10-20 ml NS Take 0.5ml & give
Cefepime- Tazobactum, Ceftriaxone, over 10min. intradermal
Cefazoline, Cefepime, Cefaperazone+
Sulbactum)

5 Meropenem, Dilute in 50 ml NS Take 0.5ml & give

over 3 hrs. intradermal
Doripenem Dilute in 50 ml NS
over 4 hrs.
Imipenem+ cilastin Dilute in 50 ml NS
over 2 hrs
6 Pipercillin-tazobactum, Ticarcilline- Dilute in 10 -20 ml NS Take 0.5ml & give
clavulanic acid, amoxycylin- over 1hr.. intradermal
Clavulanic acid

6 Linezolid over 1hrs No test dose

7 Azithromycin , Clarithromycin, Dilute 5-10 ml NS over No test dose

5min.
8 Ofloxacin, Ciprofloxacin, 100ml NS over 1hr. No test dose
Levoflaxacin, Metronidazole

9 Caspofungin, Anidulafungin 20 ml NS over ½ hr. No test dose

10 Cardarone
a) Infusion a) Dilute in 500
ml 5% dextrose
over 24 hrs
b) Bolous b) in 100 ml NS
over 1/2hrs.

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 18 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

11 Amikacin over 10 min No test dose

1. Infusion of Higher Antibiotic: Adults

S. Antibiotics Infusion Rate Test Dose

No
1 Inj. Vancomycin Dilute in 100 ml NS No test dose
over 2hrs
2 Inj. Amphoterecin Dilute in 100ml of 5% As per doctor
dextrose over 2hrs. instruction
3 Inj. Colistin One half of the total No test dose
daily dose given by
direct IV injection
over3-5min and the
remaining half diluted
in 500 ml of 5%
dextrose/ NS and given
over 23 hrs.
4 All cephalosporins(Cefotaxime, Dilute in 100 ml NS Take 0.5ml & give
Cefepime- Tazobactum, Ceftriaxone, over 30min. intradermal
Cefazoline, Cefepime, Cefaperazone+
Sulbactum)

5 Meropenem, Imipenem, Aztreonam, Dilute in 100 ml NS Take 0.5ml & give

Tigecycline, Teicoplanin over 30min. intradermal

6 Pipercillin-tazobactum, Ticarcilline- Dilute in 100 ml NS Take 0.5ml & give

clavulanic acid, amoxycylin- over 30min. intradermal
Clavulanic acid

6 Linezolid 300 ml over 2hrs No test dose

7 Azithromycin , Clarithromycin, 100 ml NS over 1hr. No test dose

8 Ofloxacin, Ciprofloxacin, 100ml NS over 1hr. No test dose

Levoflaxacin, Metronidazole

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 19 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

9 Caspofungin, Anidulafungin 100 ml NS over 1hr. No test dose

10 Cardarone
c) Infusion c) Dilute in 500
ml 5% dextrose
over 24 hrs
d) Bolous d) in 100 ml NS
over 1/2hrs.
11 Amikacin 100 ml NS over 1hr. No test dose

Annexure 1:

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 20 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 21 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 22 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Annexure 2:

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 23 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 24 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 25 of 26
 Hospital Antibiotic Policy Date of Issue :
30/09/2019
Document No : Date of Revision:
SH/AP /M/ 01 17/09/2019

Prepared by: Infection Control Committee Reviewed by: Consultants

Chairperson

Approved by: Medical Director Signature:

Page 26 of 26